Clinical trials
Observational Prostatic Neoplasms trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Recruiting | 4 |
| Unknown status | 4 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Seoul National University Hospital | 5 |
| Yonsei University | 5 |
| Asan Medical Center | 3 |
| Janssen Research & Development, LLC | 2 |
| Astellas Pharma Global Development, Inc. | 1 |
| Boryung Pharmaceutical Co., Ltd | 1 |
| Ferring Pharmaceuticals | 1 |
| GlaxoSmithKline | 1 |
| Konkuk University Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 28 |
| Breast Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Stomach Neoplasms | 3 |
| Carcinoma, Renal Cell | 2 |
| Esophageal Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
| Prostatic Hyperplasia | 2 |
| Ureteral Neoplasms | 2 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.